Cited by 30Lipoproteins and Cardiovascular HealthParaoxonase enzyme and polymorphismsCholesterol and Lipid Metabolism

Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein

Open access
Corsetti, James P., Gansevoort, Ron T., Bakker, Stephan J.L., Navis, GerJan, Sparks, Charles E., Dullaart, Robin P.F.·2012·Metabolism

Abstract

Although there is great interest in the notion that dysfunctional transformation of high-density lipoprotein (HDL) facilitates development of atherosclerosis and cardiovascular disease (CVD), few studies in human populations directly address this issue. As apolipoprotein E (apoE) is a constituent of HDL thought to be important for HDL antiatherogenic function, we sought to assess the role of apoE in CVD risk in subjects likely to display dysfunctional transformation of HDL. Association of apoE levels with incident CVD risk was investigated using Cox multivariable proportional hazards modeling. Analyses were performed in subgroups of women and men likely to display dysfunctional transformation of HDL deriving from previous subgroup identification based upon defining characteristics of concurrently high levels of HDL cholesterol and systemic inflammation as reflected by high C-reactive protein levels. Results revealed apoE levels (dichotomized as highest quartile vs combined 3 lowest quartiles) as predicting subgroup risk in women (hazard ratio, 4.52; 95% confidence interval, 1.07-19.12; P = .040) but not in men. Further sex differences were manifested in terms of the relationship of apoE levels with age. Analysis revealed positive correlation of apoE levels with age in women (r = 0.47, P < .0001) but not in men (r = 0.04, P = .43). Apolipoprotein E levels predict incident CVD risk in women with high levels of HDL cholesterol and C-reactive protein but not in men. Future studies should be oriented toward investigations of apoE as related to multiplicity of HDL functionality and toward assessment of potential roles for apoE in dysfunctional transformation of HDL.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.metabol.2011.11.010

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Rasmussen et al. showed that adjustment for C-reactive protein did not have any impact on the risk between plasma levels of apoE and ischemic heart disease.

    “The importance of high C-reactive protein levels has been investigated by some studies, however Rasmussen et al. showed that adjustment for C-reactive protein did not have any impact on the risk between plasma levels of apoE and ischemic heart disease [44,116,121,122].”

    From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [121]

    The Discussion (section 4; page not given) says apoE-associated risk was absent in women with high HDL-C and low CRP, while the Results (section 3.3; page not given) report risk in the high-CRP subgroup. That is contrary to the claim that CRP had no impact on the association. The paper also does not report a Rasmussen analysis of CRP adjustment. (LLM, conf=0.76)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. Florentin M, Liberopoulos EN, Wierzbicki AS, et al. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008;23: 370-8.
  2. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels. J Am CollCardiol 2008;51: 2199-211.
  3. Sviridov D, Mukhamedova N, Remaley AT, et al. Antiathero- genic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 2008;15:52-62.
  4. Ragbir S, Farmer JA. Dysfunctional high-density lipoprotein and atherosclerosis. Curr Atheroscler Rep 2010;12:343-8.
  5. Shao B, Oda M, Oram JF, et al. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipopro- tein. Chem Res Toxicol 2010;23:447-54.
  6. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007;18:427-34.
  7. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006;58:342-74.
  8. Onat A, Hergene G. Low-grade inflammation, and dysfunc- tion of high-density lipoprotein and its apolipoproteins as a major driver of cardiovascular risk. Metab Clin Exp 2011;60: 499-512.
  9. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concen- tration and ischemic heart disease. Circulation 1998;97: 1029-36.
  10. von Eckardstein A, Schulte H, Assmann G. Increased risk of myocardial infarction in men with both hypertriglyceridemia and elevated HDL cholesterol. Circulation 1999;99:1925.
  11. Bittner V, Simon JA, Fong J, et al. Correlates of high HDL cholesterol among women with coronary heart disease. Am Heart J 2000;139:288-96.
  12. Shimoni N, Kaplan M, Keidar S. Cardiovascular diseases in patients with high levels of plasma high density lipoprotein: association with increased plasma oxidative state. Israel Med Association J 2003;5:702-5.
  13. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000;101:1907-12.
  14. Gnasso A, Motti C, Irace C, et al. The ARG allele in position 192 of PON1 is associated with carotid atherosclerosis in subjects with elevated HDLs. Atherosclerosis 2002;164:289-95.
  15. deLemos AS, Wolfe ML, Long CJ, et al. Identification of genetic variants in endothelial lipase in persons with elevated high- density lipoprotein cholesterol. Circulation 2002;106:1321-6.
  16. Ma K, Cilingiroglu M, Otvos JD, et al. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. PNAS 2003;100: 2748-53.
  17. Broedl UC, Jin W, Rader DJ. Endothelial lipase: a modulator of lipoprotein metabolism upregulated by inflammation. Trends Cardiovasc Med 2004;14:202-6.
  18. Grundy SM, Vega GL, Otvos JD, et al. Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men: genetic and pharmacological evidence. J Lipid Res 1999;40:229-34.
  19. Ruel IL, Couture P, Cohn JS, et al. Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism. J Lipid Res 2004;45:1528-37.
  20. Corsetti JP, Gansevoort RT, Sparks CE, et al. HDL protection against primary cardiac risk is lost with inflammation. Eur J Clin Invest 2010;40:483-9.
  21. Corsetti JP, Gansevoort RT, Navis GJ, et al. LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP. Atherosclerosis 2011;214:373-6.
  22. Corsetti JP, Ryan D, Rainwater DL, et al. CETP polymorphism (TaqIB) associates with risk in postinfarction patients with high HDL cholesterol and high CRP levels. Arterioscler Thromb Vasc Biol 2010;30:1657-64.
  23. Corsetti JP, Ryan D, Moss AJ, et al. NAD(P)H oxidase polymorphism (C242T) and high HDL-C associate with recurrent coronary events in post infarction patients. Atherosclerosis 2007;196:461-8.
  24. Huang Y. Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr Opin Lipidol 2010;21:337-45.
  25. Greenow K, Pearce NJ, Ramji DP. The key role of apolipopro- tein E in atherosclerosis. J Mol Med 2005;83:329-42.
  26. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 2008;52:131-45.
  27. Pinto-Sietsma SJ, Janssen WMT, Hillege HL, et al. Urinary albumin excretion is associated with renal functional ab- normalities in a non-diabetic population. J Am Soc Nephrol 2000;11:1882-8.
  28. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, et al. Albuminuria assessed from first-morning-void urine samples versus 24 hour urine collections as a predictor of cardiovas- cular morbidity and mortality. Am J Epidemiol 2008;168: 897-905.
  29. Verhave JD, Gansevoort RT, Hillege HL, et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 2004;66:S18-21.
  30. Borggreve SE, Hillege HL, Wolffenbuttel BHR, et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006;91: 3382-8.
  31. Corsetti JP, Zareba W, Moss AJ, et al. Serum glucose and triglyceride determine high-risk subgroups in non- diabetic postinfarction patients. Atherosclerosis 2005;183: 293-300.
  32. Reilly M, Rader DJ. Apolipoprotein E and coronary disease: a puzzling paradox. PLoS Med 2006;3:736-8.
  33. Soderlund S, Watanabe H, Ehnholm C, Jauhiainen M, et al. Increased apolipoprotein E level and reduced high-density lipoprotein mean particle size associate with low high- density lipoprotein cholesterol and features of metabolic syndrome. Metab Clin Exp 2010;60:1502-9.
  34. Huang Y, Liu XQ, Rall SC, et al. Overexpression and accumulation of apolipoprotein E as a cause of hypertrigly- ceridemia. J Biol Chem 1998;273:26388-93.

Authors
Corsetti, J. P., Gansevoort, R. T., Bakker, S. J. L., Navis, G., Sparks, C. E., & Dullaart, R. P. F.
Affiliations
  • University of Rochester Medicine (US)
  • University Medical Center Groningen (NL)
Corresponding author
Corsetti, James P.
Venue
Metabolism
Publisher
Elsevier BV
Published
2012-07
Volume
61
Issue
7
Pages
996-1002
ISSN
0026-0495 (ISSN-L)
OpenAlex
W2101459296
Cited by
30
References
2
Citations by year
2026: 1 · 2025: 2 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 5 · 2018: 4 · 2017: 1 · 2016: 4 · 2015: 2 · 2013: 3 · 2012: 3
FWCI
2.61
Type
journal article
Language
en
Open access
Locations
  • Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
apolipoprotein E, cardiovascular risk, HDL cholesterol, C-reactive protein, sex differences, systemic inflammation, atherosclerosis, HDL function
MeSH terms
Adult, Apolipoproteins E, C-Reactive Protein, Cardiovascular Diseases, Female, Humans, Cholesterol, HDL, Longitudinal Studies, Male, Middle Aged, Risk, Sex Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review